Cargando…

Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer

Bladder cancer (BC) is a common urological cancer of high mortality and recurrence rates. Currently, cystoscopy is performed as standard examination for the diagnosis and subsequent monitoring for recurrence of the patients. Frequent expensive and invasive procedures may deterrent patients from regu...

Descripción completa

Detalles Bibliográficos
Autores principales: Nizioł, Joanna, Ossoliński, Krzysztof, Płaza-Altamer, Aneta, Kołodziej, Artur, Ossolińska, Anna, Ossoliński, Tadeusz, Ruman, Tomasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452537/
https://www.ncbi.nlm.nih.gov/pubmed/36071106
http://dx.doi.org/10.1038/s41598-022-19576-9
_version_ 1784784931577135104
author Nizioł, Joanna
Ossoliński, Krzysztof
Płaza-Altamer, Aneta
Kołodziej, Artur
Ossolińska, Anna
Ossoliński, Tadeusz
Ruman, Tomasz
author_facet Nizioł, Joanna
Ossoliński, Krzysztof
Płaza-Altamer, Aneta
Kołodziej, Artur
Ossolińska, Anna
Ossoliński, Tadeusz
Ruman, Tomasz
author_sort Nizioł, Joanna
collection PubMed
description Bladder cancer (BC) is a common urological cancer of high mortality and recurrence rates. Currently, cystoscopy is performed as standard examination for the diagnosis and subsequent monitoring for recurrence of the patients. Frequent expensive and invasive procedures may deterrent patients from regular follow-up screening, therefore it is important to look for new non-invasive methods to aid in the detection of recurrent and/or primary BC. In this study, ultra-high-performance liquid chromatography coupled with ultra-high-resolution mass spectrometry was employed for non-targeted metabolomic profiling of 200 human serum samples to identify biochemical signatures that differentiate BC from non-cancer controls (NCs). Univariate and multivariate statistical analyses with external validation revealed twenty-seven metabolites that differentiate between BC patients from NCs. Abundances of these metabolites displayed statistically significant differences in two independent training and validation sets. Twenty-three serum metabolites were also found to be distinguishing between low- and high-grade of BC patients and controls. Thirty-seven serum metabolites were found to differentiate between different stages of BC. The results suggest that measurement of serum metabolites may provide more facile and less invasive diagnostic methodology for detection of bladder cancer and recurrent disease management.
format Online
Article
Text
id pubmed-9452537
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-94525372022-09-09 Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer Nizioł, Joanna Ossoliński, Krzysztof Płaza-Altamer, Aneta Kołodziej, Artur Ossolińska, Anna Ossoliński, Tadeusz Ruman, Tomasz Sci Rep Article Bladder cancer (BC) is a common urological cancer of high mortality and recurrence rates. Currently, cystoscopy is performed as standard examination for the diagnosis and subsequent monitoring for recurrence of the patients. Frequent expensive and invasive procedures may deterrent patients from regular follow-up screening, therefore it is important to look for new non-invasive methods to aid in the detection of recurrent and/or primary BC. In this study, ultra-high-performance liquid chromatography coupled with ultra-high-resolution mass spectrometry was employed for non-targeted metabolomic profiling of 200 human serum samples to identify biochemical signatures that differentiate BC from non-cancer controls (NCs). Univariate and multivariate statistical analyses with external validation revealed twenty-seven metabolites that differentiate between BC patients from NCs. Abundances of these metabolites displayed statistically significant differences in two independent training and validation sets. Twenty-three serum metabolites were also found to be distinguishing between low- and high-grade of BC patients and controls. Thirty-seven serum metabolites were found to differentiate between different stages of BC. The results suggest that measurement of serum metabolites may provide more facile and less invasive diagnostic methodology for detection of bladder cancer and recurrent disease management. Nature Publishing Group UK 2022-09-07 /pmc/articles/PMC9452537/ /pubmed/36071106 http://dx.doi.org/10.1038/s41598-022-19576-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Nizioł, Joanna
Ossoliński, Krzysztof
Płaza-Altamer, Aneta
Kołodziej, Artur
Ossolińska, Anna
Ossoliński, Tadeusz
Ruman, Tomasz
Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer
title Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer
title_full Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer
title_fullStr Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer
title_full_unstemmed Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer
title_short Untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer
title_sort untargeted ultra-high-resolution mass spectrometry metabolomic profiling of blood serum in bladder cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452537/
https://www.ncbi.nlm.nih.gov/pubmed/36071106
http://dx.doi.org/10.1038/s41598-022-19576-9
work_keys_str_mv AT niziołjoanna untargetedultrahighresolutionmassspectrometrymetabolomicprofilingofbloodseruminbladdercancer
AT ossolinskikrzysztof untargetedultrahighresolutionmassspectrometrymetabolomicprofilingofbloodseruminbladdercancer
AT płazaaltameraneta untargetedultrahighresolutionmassspectrometrymetabolomicprofilingofbloodseruminbladdercancer
AT kołodziejartur untargetedultrahighresolutionmassspectrometrymetabolomicprofilingofbloodseruminbladdercancer
AT ossolinskaanna untargetedultrahighresolutionmassspectrometrymetabolomicprofilingofbloodseruminbladdercancer
AT ossolinskitadeusz untargetedultrahighresolutionmassspectrometrymetabolomicprofilingofbloodseruminbladdercancer
AT rumantomasz untargetedultrahighresolutionmassspectrometrymetabolomicprofilingofbloodseruminbladdercancer